Assessing variants across all genes (BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53) in our study also found 11.7% of New Zealand patients carrying a variant of unknown significance, which was comparable to similar international breast cancer studies (6.4% [30]; 9.9% [27]; 14.7% [31]). This evidence concerns the gene CDH1 and breast carcinoma.